

# Emesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/E7CCEC51A007EN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: E7CCEC51A007EN

## Abstracts

The 7 major emesis markets are expected to exhibit a CAGR of 4.18% during 2024-2034.

The emesis market has been comprehensively analyzed in IMARC's new report titled "Emesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Emesis, commonly known as vomiting, is a physiological process characterized by the forceful expulsion of abdominal contents through the mouth and sometimes the nose. It is a complex reflex involving the coordination of muscles in the stomach, diaphragm, and abdominal wall. Emesis helps to expel harmful substances or irritants from the body and can be accompanied by a variety of symptoms. The indications preceding or accompanying this condition range from a sensation of nausea, increased salivation, and an uncomfortable feeling in the upper abdomen to palpitations, lightheadedness, and a fast heartbeat. The ailment can be distressing, weakening, and it may also lead to dehydration if not managed properly. Diagnosing the underlying cause of emesis requires a thorough medical evaluation. Physicians take into consideration the patient's medical history, the duration and frequency of vomiting, associated symptoms, and any potential triggers. Various diagnostic tools, like blood tests, imaging studies, and endoscopic procedures might be conducted to identify the root cause.

The increasing prevalence of numerous associated risk factors, including gastroenteritis, food poisoning, motion sickness, peptic ulcers, excessive alcohol consumption, etc., is primarily driving the emesis market. In addition to this, the inflating utilization of efficacious treatments, such as antiemetic medications, serotonin receptor antagonists, dopamine antagonists, and neurokinin-1 receptor antagonists to effectively mitigate the condition and prevent further complications is creating a positive outlook for

the market. Moreover, the widespread adoption of dietary modifications and lifestyle adjustments, as they aid in minimizing triggers, managing symptoms, and enhancing overall well-being, is also bolstering the market growth. Apart from this, the rising usage of behavioral therapies, which encompass cognitive-behavioral techniques and biofeedback mechanisms, to address underlying triggers and promote healthier responses in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of acupuncture and acupressure interventions, since they focus on specific pressure points that help in regulating the body's nausea response, is also augmenting the market growth. Furthermore, the escalating application of innovative medical devices, such as transcutaneous electrical nerve stimulation (TENS) procedures, which target certain neural pathways to alleviate vomiting in individuals suffering from the condition, is expected to drive the emesis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the emesis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for emesis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the emesis market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the emesis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the emesis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current emesis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the emesis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the emesis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the emesis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of emesis across the seven major markets?

What is the number of prevalent cases (2018-2034) of emesis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of emesis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with emesis across the seven major markets?

What is the size of the emesis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of emesis?

What will be the growth rate of patients across the seven major markets?

### Emesis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for emesis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the emesis market?

What are the key regulatory events related to the emesis market?

What is the structure of clinical trial landscape by status related to the emesis market?

What is the structure of clinical trial landscape by phase related to the emesis market?

What is the structure of clinical trial landscape by route of administration related to the emesis market?

## Contents

1 Preface

### **2 SCOPE AND METHODOLOGY**

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 EMESIS - INTRODUCTION**

4.1 Overview

4.2 Regulatory Process

4.3 Epidemiology (2018-2023) and Forecast (2024-2034)

4.4 Market Overview (2018-2023) and Forecast (2024-2034)

4.5 Competitive Intelligence

### **5 EMESIS - DISEASE OVERVIEW**

5.1 Introduction

5.2 Symptoms and Diagnosis

5.3 Pathophysiology

5.4 Causes and Risk Factors

5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 EMESIS - EPIDEMIOLOGY AND PATIENT POPULATION**

7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 EMESIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 EMESIS - UNMET NEEDS**

## **10 EMESIS - KEY ENDPOINTS OF TREATMENT**

## **11 EMESIS - MARKETED PRODUCTS**

- 11.1 List of Emesis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Aloxi (Palonosetron intravenous) - Helsinn Healthcare
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Barhemsys (Amisulpride) - Acacia Pharma
    - 11.1.2.1 Drug Overview
    - 11.1.2.2 Mechanism of Action



- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Sustol® (Granisetron) - Heron Therapeutics
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Varubi (Rolapitant) - TerSera Therapeutics
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Zofran (Ondansetron Hydrochloride) - GlaxoSmithKline
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 EMESIS - PIPELINE DRUGS**

- 12.1 List of Emesis Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 TAK-951 - Takeda
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 CL-108 - Charleston Laboratories
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy
    - 12.1.2.5 Regulatory Status

### 12.1.3 Staccato Granisetron - Alexza Pharmaceuticals

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

### 12.1.4 STAR-OLZ - Starton Therapeutics

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. EMESIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. EMESIS – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### **15 EMESIS - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Emesis - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Emesis - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Emesis - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Emesis - Market Size by Therapies

- 15.3.2.1 Market Size by Therapies (2018-2023)
- 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Emesis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Emesis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Emesis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Emesis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Emesis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Emesis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Emesis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Emesis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Emesis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Emesis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Emesis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Emesis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Emesis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Emesis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)

- 15.8.2 Emesis - Market Size by Therapies
  - 15.8.2.1 Market Size by Therapies (2018-2023)
  - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Emesis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Emesis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Emesis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Emesis - Access and Reimbursement Overview

## **16 EMESIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 EMESIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 EMESIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Emesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/E7CCEC51A007EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E7CCEC51A007EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

